UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2304-3
Program Prior Authorization/Medical Necessity
Medication Skyclarys® (omaveloxolone)
P&T Approval Date 5/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Skyclarys (omaveloxolone) is indicated for the treatment of Friedreich’s ataxia in adults and
adolescents aged 16 years and older.
2. Coverage Criteriaa:
A. Initial Authorization
1. Skyclarys will be approved based on all of the following criteria:
a. Diagnosis of Friedreich’s ataxia
-AND-
b. Confirmed presence of a mutation in the frataxin (FXN) gene
-AND-
c. Prescribed by, or in consultation with, one of the following:
(1) Neurologist
(2) Neurogeneticist
(3) Physical Medicine and Rehabilitation physician (i.e., physiatrist)
Authorization will be issued for 12 months.
B. Reauthorization
1. Skyclarys will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Skyclarys therapy
-AND-
b. Prescribed by, or in consultation with, one of the following:
(1) Neurologist
(2) Neurogeneticist
(3) Physical Medicine and Rehabilitation physician (i.e., physiatrist)
© 2025 UnitedHealthcare Services, Inc.
1
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Skyclarys [package insert]. Plano, TX: Reata Pharmaceuticals, Inc.; December 2024.
Program Prior Authorization/Medical Necessity – Skyclarys (omaveloxolone)
Change Control
5/2023 New program.
5/2024 Annual review with no updates to coverage criteria. Updated references.
5/2025 Annual review with no updates to coverage criteria. Updated reference.
© 2025 UnitedHealthcare Services, Inc.
2